Radiation boost may help control advanced pancreatic cancer
NCT ID NCT07600268
First seen May 23, 2026 · Last updated Jun 22, 2026 · Updated 6 times
Summary
This phase II trial tests whether adding a precise, high-dose form of radiation (SBRT) to standard maintenance chemotherapy can help people with advanced pancreatic cancer live longer. The study enrolls 24 adults whose cancer has not grown after at least four months of initial chemo. Participants are randomly assigned to receive either maintenance chemo alone or maintenance chemo plus SBRT. The main goal is to see if the combination improves one-year survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital and Institute
RECRUITINGJinan, Shandong, 250021, China
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiotherapy (SBRT) plus maintenance chemotherapy
What this could lead to
If successful, this could offer a new way to extend survival for people with advanced pancreatic cancer by adding targeted radiation to standard maintenance therapy.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply to everyone. The added radiation also carries risks like fatigue or digestive issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.